REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.26+0.02 (+0.28%)
Close on Nov 18, 2026Market cap $479.26MP/E –Yield –
Regenxbio pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Regenxbio's pe ratio was 13.6× on Jan 31, 2023, against 18.5× a year earlier. Over the last 2 years it ranged from 8.8× to 51.6×, with a median of 18.5×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Jan 31, 2023 | 13.6× | +0.3 |
| 2022 | Dec 30, 2022 | 13.3× | −5.1 |
| 2019 | Apr 30, 2019 | 18.5× | −0.0 |
| 2018 | Dec 31, 2018 | 18.5× | – |
See a number that looks wrong?